title: Effects of the hematoregulatory peptide SK&F 107647 alone and in combination with amphotericin B against disseminated candidiasis in persistently neutropenic rabbits.
abstract: The effects of the hematoregulatory peptide SK&F 107647 were examined in a persistently and profoundly neutropenic rabbit model of disseminated candidiasis in order to determine its potential to enhance resistance against infection and its role as an adjunct to conventional antifungal chemotherapy. In healthy animals, SK&F 107647 elicited a time-dependent increase in CD11b-positive monocytes and neutrophils. When administered to neutropenic rabbits infected with Candida albicans, no significant differences in the number of CFU per gram in any of the tissues tested compared with the number in untreated control rabbits were detected. However, when SK&F 107647 was administered in combination with low doses of amphotericin B, there was a significant reduction in organism burden in the lungs, liver, spleen, and kidneys compared with the burdens in the organs of untreated control animals and in the lungs and kidneys compared with the burdens in the lungs and kidneys of animals treated with amphotericin B alone. These data suggest a potential role for this peptide as adjunctive therapy in combination with conventional antifungal agents in the treatment of disseminated candidiasis in the setting of profound and persistent neutropenia.
authors.affiliation: Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA. lymanc@mail.nih.gov
authors.forename: C A
authors.initials: CA
authors.lastname: Lyman
authors.forename: C
authors.initials: C
authors.lastname: Gonzalez
authors.forename: M
authors.initials: M
authors.lastname: Schneider
authors.forename: J
authors.initials: J
authors.lastname: Lee
authors.forename: T J
authors.initials: TJ
authors.lastname: Walsh
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000666:Amphotericin B / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy*; D003561:Cytarabine / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D009503:Neutropenia / Q000139:chemically induced; D009842:Oligopeptides / Q000627:therapeutic use*; D011817:Rabbits
chemical_list: D000276:Adjuvants, Immunologic; D000935:Antifungal Agents; D009842:Oligopeptides; D003561:Cytarabine; C086049:SK&F 107647; D000666:Amphotericin B